Crinetics Pharmaceuticals Inc
CRNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9B
Close$
$-11.31
113.3% downside
Current Fair Value
113.3% downsideOvervalued by 113.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.00 Billion |
|---|---|
| Enterprise Value | $8.95 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.95 |
| Beta | 0.13 |
| Outstanding Shares | 105,560,000 |
Return
| Return on Equity | -42.08% |
|---|---|
| Return on Assets | -37.95% |
| Return on Invested Capital | -43.32% |
Valuation & Multiples
| P/E Ratio | -16.82 |
|---|---|
| PEG | -372.79 |
| Price to Sales | - |
| Price to Book Ratio | 7.72 |
| Enterprise Value to Revenue | 224.38 |
| Enterprise Value to EBIT | -16.63 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.23
Average shareholder expectationRevenue Estimate
$14.82 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.20
Average shareholder expectationRevenue Estimate
$21.04 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7521▼ 29.87% |
|---|---|
| Total Calls | 60,500▼ 6.92% |
| Total Puts | 45,500▼ 33.38% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 121.51%▲ 3.57% |
|---|---|
| Total Invested | $4.76B▲ 6.75% |
| Investors Holding | 273▲ 24.00% |
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers